This finding is striking since we also found that adding 5 μM Sorafenib increased the expression of activated p‐STAT3 in 2 HCC cell lines, suggesting that increased p‐STAT3 expression might be an unwanted side effect for Sorafenib therapy to suppress HCC progression. Here, STAT3 is linked to hepatocellular carcinoma.